1. Audit Status of the 2025 Financial Statements
The financial statements for the year 2025 have been prepared in accordance with accounting standards and fairly reflect the financial position of the company as of December 31, 2025, as well as the operating results and cash flows for the year. The financial statements have been audited by Grant Thornton (Special General Partnership), which issued a standard unqualified audit report (No. 110A006327). The main financial data reflected in the financial statements is reported as follows:
2. Financial Settlement for 2025
(1) Asset Situation
| Item | End of 2025 (CNY) | End of 2024 (CNY) | Change (%) |
|---|---|---|---|
| Cash and cash equivalents | 88,134,170.56 | 75,262,690.31 | 17.10% |
| Trading financial assets | 1,473,900,144.47 | 1,496,350,629.65 | -1.50% |
| Notes receivable | 2,476,306.12 | 3,432,332.03 | -27.85% |
| Accounts receivable | 42,398,681.03 | 47,320,922.37 | -10.40% |
| Prepayments | 19,713.80 | 130,457.75 | -84.89% |
| Other receivables | 948,161.59 | 1,434,421.68 | -33.90% |
| Inventory | 68,850,757.57 | 81,369,540.32 | -15.39% |
| Other current assets | 10,802,498.14 | 6,342,903.15 | 70.31% |
| Long-term equity investments | 709,580,877.36 | 706,402,153.78 | 0.45% |
| Other non-current financial assets | 223,649,698.99 | 251,480,159.97 | -11.07% |
| Fixed assets | 438,447,032.63 | 476,948,391.45 | -8.07% |
| Construction in progress | 11,293,481.70 | 11,032,073.70 | 2.37% |
| Productive biological assets | 13,760,630.91 | 7,007,245.01 | 96.38% |
| Right-of-use assets | 11,342,923.39 | 11,693,735.50 | -3.00% |
| Intangible assets | 44,679,819.05 | 47,118,981.89 | -5.18% |
| Development expenditures | 366,905,803.63 | 292,706,479.20 | 25.35% |
| Goodwill | 21,865,087.82 | 21,865,087.82 | 0.00% |
| Deferred tax assets | 2,282,959.52 | 1,787,957.56 | 27.69% |
| Other non-current assets | 37,064,000.33 | 12,162,402.33 | 204.74% |
| Total Assets | 3,568,402,748.61 | 3,551,848,565.47 | 0.47% |